ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.
IPO Year: 2012
Exchange: NASDAQ
Website: chemocentryx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/4/2022 | $81.00 | Buy | Canaccord Genuity |
| 11/10/2021 | $107.00 → $110.00 | Strong Buy | Raymond James |
| 10/11/2021 | $14.00 → $38.00 | Underweight → Neutral | JP Morgan |
| 10/11/2021 | $64.00 | Mkt Perform → Outperform | SVB Leerink |
| 10/11/2021 | $62.00 → $107.00 | Outperform → Strong Buy | Raymond James |
| 10/8/2021 | $62.00 → $107.00 | Outperform → Strong Buy | Raymond James |
| 10/8/2021 | Neutral → Overweight | Piper Sandler | |
| 7/7/2021 | $26.00 → $31.00 | Hold → Buy | Stifel |
4 - ChemoCentryx, Inc. (0001340652) (Issuer)
4 - ChemoCentryx, Inc. (0001340652) (Issuer)
4 - ChemoCentryx, Inc. (0001340652) (Issuer)
4 - ChemoCentryx, Inc. (0001340652) (Issuer)
4 - ChemoCentryx, Inc. (0001340652) (Issuer)
4 - ChemoCentryx, Inc. (0001340652) (Issuer)
4 - ChemoCentryx, Inc. (0001340652) (Issuer)
4 - ChemoCentryx, Inc. (0001340652) (Issuer)
4 - ChemoCentryx, Inc. (0001340652) (Issuer)
4 - ChemoCentryx, Inc. (0001340652) (Issuer)
Submission status for CHEMOCENTRYX, INC.'s drug TAVNEOS (ORIG-1) with active ingredient AVACOPAN has changed to 'Approval' on 10/07/2021. Application Category: NDA, Application Number: 214487, Application Classification: Type 1 - New Molecular Entity
SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. "With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS® (avacopan) commercial efforts," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Jennifer's values closely align with our organization, and we are confident this addition
Appointment Brings More than 20 Years of Drug Development Experience as Company Launches First Product SAN CARLOS, Calif., Oct. 11, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the appointment of Rita I. Jain, M.D., as Executive Vice President, Chief Medical Officer. In this role, she will oversee development activities including clinical development, development operations, regulatory affairs, and drug safety and pharmacovigilance. Dr. Jain will continue to serve on the ChemoCentryx board of directors (where she has served since March of 2019) as an executive employee director. Dr. Jain, a board-certified rheumatologist, brings more than 20 years of drug de
MOUNTAIN VIEW, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Susan M. Kanaya, the Company’s Executive Vice President and Chief Financial and Administrative Officer, to the ChemoCentryx Board of Directors effective March 2, 2021. “Susan Kanaya’s many fundamental contributions have been key to ChemoCentryx’s growth and prosperity,” said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. “Over many formative years of our enterprise, she ensured our strong financial position, allowing us to achieve our operational plans and thus increasing shareholder value while serving patients’ needs. As a
-- The New England Journal of Medicine highlights results of ADVOCATE Phase III trial of avacopan in ANCA-associated vasculitis -- -- Applications for regulatory approval of avacopan in ANCA-associated vasculitis under review in the U.S. (PDUFA goal date of July 7, 2021), the E.U. (decision expected in H2 2021) and Japan -- -- Topline data from AURORA Phase II clinical trial of avacopan in Hidradenitis Suppurativa (HS) leads to Company plans for Phase III trial of avacopan in patients with most severe form of HS -- -- Topline Results of ACCOLADE Phase II clinical trial of avacopan in C3 Glomerulopathy (C3G) include improved estimated Glomerular Filtration Rate (eGFR); Company plans
-- Brings more than two decades of executive management experience from global pharmaceutical companies -- MOUNTAIN VIEW, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced the appointment of Tausif (‘Tosh’) Butt as Executive Vice President and Chief Operating Officer, reporting directly to President and Chief Executive Officer Thomas J. Schall, Ph.D. In this new capacity at ChemoCentryx, Tosh Butt will oversee many of the Company’s operational functions, and further strengthen the commercial infrastructure that ChemoCentryx has developed in anticipation of the launch of avacopan for the treatment of ANCA-associated vasculitis. A New Drug Applica
TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl
-- Planned posters and an oral presentation will highlight data from the trials that supported the approval of TAVNEOS® (avacopan) for patients with ANCA-associated vasculitis; additional poster will cover expression of kidney C5aR -- SAN CARLOS, Calif., Oct. 17, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced planned presentations covering TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, at the American Society of Nephrology (ASN) Kidney Week 2022 and American College of Rheumatology (ACR) Convergence 2022 annual meetings taking place in November. American Society of Nephrology Kidney Week 2022, November 3-6, Orlan
-- Two poster presentations planned for CCX559, including results from ongoing Phase I clinical study in patients with advanced solid tumors, and preclinical evidence from murine model -- SAN CARLOS, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced two upcoming poster presentations for CCX559, the Company's investigational, highly potent, orally administered PD-L1 checkpoint inhibitor, at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, held November 8-12, 2022, in Boston, MA. ChemoCentryx Poster Presentations at SITC 37th Annual Meeting (November 8-12, 2022): Results From an Ongoing Open-Label, Multicenter, Phase 1 Trial of
SAN CARLOS, Calif., Aug. 24, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced planned poster presentations at three upcoming medical conferences taking place in August and September, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis, as well as the role of C5a and C5aR in severe hidradenitis suppurativa (HS) and lupus nephritis (LN). 18th European Meeting on Complement in Human Disease (EMCHD) Date: August 26-29, 2022Location: Bern, SwitzerlandPosters: Seven (7) encore posters are planned, highlighting TAVNEOS for the treatment of ANCA-associated vasculitis,
SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022. About ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer.
Acquisition Includes TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Serious Autoimmune Disease Tavneos Adds to Amgen's Decades-Long Leadership in Inflammation and Nephrology THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and ChemoCentryx, Inc., (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, today announced that the companies have entered into a definitive agreement under which Amgen will acquire ChemoCentryx for $52 per share in cash, representing an enterprise value of approximately $3.7 billion.
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (International). The conference ID number is 9726781. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast wil
SAN CARLOS, Calif., July 05, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that Jennifer L. Herron has been appointed to the Board as an independent director, effective June 28, 2022. With this appointment, the Board increases the number of directors constituting the whole Board from eight to nine. "With more than 25 years developing and refining her therapeutics commercial expertise, Jennifer is uniquely positioned to add immediate value to our TAVNEOS® (avacopan) commercial efforts," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "Jennifer's values closely align with our organization, and we are confident this addition
-- Consistent with approved antibody inhibitors of PD-L1, CCX559 demonstrates immunomodulatory activity in first cycle of treatment -- -- Safety and tolerability allow for continued dose escalation with no dose limiting toxicities to date -- SAN CARLOS, Calif., June 06, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the presentation of safety results from the ongoing Phase I clinical study of CCX559, the Company's highly potent, orally administered PD-L1 checkpoint inhibitor, in patients with advanced solid tumors during a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. In the ASCO poster titled, Results From an Ongoin
SAN CARLOS, Calif., May 31, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced upcoming abstract presentations at three key medical conferences taking place in June, which highlight TAVNEOS® (avacopan), an orally administered selective complement 5a receptor (C5aR) inhibitor, and its role in ANCA-associated vasculitis and potential application in C3 glomerulopathy, as well as the immuno-oncology potential of CCX559, an orally administered small molecule PD-L1 inhibitor. European Alliance of Associations for Rheumatology (EULAR), June 1-4, Copenhagen Effect of Avacopan on Relapse Rates and Relapse-Free Time in Patients with ANCA-Associated Vasculitis: Results of t
15-12G - ChemoCentryx, Inc. (0001340652) (Filer)
S-8 POS - ChemoCentryx, Inc. (0001340652) (Filer)
S-8 POS - ChemoCentryx, Inc. (0001340652) (Filer)
POSASR - ChemoCentryx, Inc. (0001340652) (Filer)
8-K - ChemoCentryx, Inc. (0001340652) (Filer)
8-K - ChemoCentryx, Inc. (0001340652) (Filer)
DEFA14A - ChemoCentryx, Inc. (0001340652) (Filer)
8-K - ChemoCentryx, Inc. (0001340652) (Filer)
DEFA14A - ChemoCentryx, Inc. (0001340652) (Filer)
DEFM14A - ChemoCentryx, Inc. (0001340652) (Filer)
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13D/A - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13G - ChemoCentryx, Inc. (0001340652) (Subject)
SC 13G/A - ChemoCentryx, Inc. (0001340652) (Subject)
TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., Oct. 20, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ:CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer, for $52 per share in cash, representing aggregate merger consideration of approximately $3.7 billion. "ChemoCentryx enhances Amgen's leading inflammation and nephrology portfolio and includes TAVNEOS® (avacopan), a first-in-cl
SAN CARLOS, Calif., Aug. 09, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022. About ChemoCentryx ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer.
SAN CARLOS, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's second quarter 2022 financial results will be released after market close on Tuesday, August 9, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on August 9, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (800) 715-9871 (Domestic) or (646) 307-1963 (International). The conference ID number is 9726781. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast wil
-- Five-fold increase in net sales of TAVNEOS® (avacopan) quarter-over-quarter with $5.4 million in Q1 2022 -- -- Marked growth in key performance indicators (Q1 2022 to Q4 2021 comparison): - 195% TAVNEOS new Patient Start Forms - 275% Unique Prescribers - 308% Patients on Drug -- -- Global expansion continues with approvals in European Union (EU) and Canada; $45 million milestone received from TAVNEOS EU approval -- -- Positive Phase I data on pharmacokinetics (PK) and pharmacodynamics (PD) including evidence of immune activation for once daily, orally administered PD-L1 inhibitor, CCX559 -- -- Well capitalized with approximately $371.8 million in cash and investments as of Marc
SAN CARLOS, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's first quarter 2022 financial results will be released after market close on Thursday, May 5, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on May 5, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 6597218. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will rem
-- Total revenue of $32.2 million in 2021 with $2.3 million in Q4; TAVNEOS® (avacopan) US net product sales of approximately $1.0 million in Q4 2021 following US Food and Drug Administration (FDA) approval in ANCA-associated vasculitis -- -- TAVNEOS also approved in European Union (EU) triggering $45 million milestone from Vifor Pharma received in Q1 2022 -- -- Company plans to initiate clinical development for TAVNEOS in lupus nephritis (LN) and to meet with FDA on the path forward in severe hidradenitis suppurativa (HS) and C3 glomerulopathy (C3G) in 2022 -- -- Dose escalation in Phase I study of orally-administered PD-L1/PD-1 checkpoint inhibitor, CCX559, expected to complete in 2022;
MOUNTAIN VIEW, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's fourth quarter and full year 2021 financial results will be released after market close on Tuesday, March 1, 2022. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on March 1, 2022 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 3136966. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The a
-- U.S. Food & Drug Administration (FDA) approves TAVNEOSTM (avacopan) in ANCA-Associated Vasculitis in October -- -- TAVNEOS now launched in the U.S. -- -- TAVNEOS approved also in Japan; European CHMP opinion expected this month -- -- Pipeline advances: Company intends to meet with FDA on path for TAVNEOS in C3 Glomerulopathy (C3G) and Hidradenitis Suppurativa (HS); plans to initiate clinical development of TAVNEOS in Lupus Nephritis (LN) in 2022 -- -- Clinical development underway of next generation orally-administered immune checkpoint inhibitor CCX559 -- -- $372 million in cash and investments at September 30, 2021 -- -- Conference call today at 5:00 p.m. Eastern Time -- SAN CA
MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on November 9, 2021 to discuss these results and to answer questions. To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 7270887. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webca
-- First FDA-approved orally-administered inhibitor of the complement 5a receptor -- -- Company to hold conference call at 8:30 a.m. Eastern Time -- SAN CARLOS, Calif., Oct. 08, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ:CCXI), today announced that the U.S. Food and Drug Administration (FDA) has approved TAVNEOS (avacopan), an orally administered selective complement 5a receptor inhibitor, as an adjunctive treatment of adult patients with severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (also known as ANCA-associated vasculitis or ANCA vasculitis), specifically granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA) (the two main fo
Canaccord Genuity resumed coverage of ChemoCentryx with a rating of Buy and set a new price target of $81.00
Raymond James reiterated coverage of ChemoCentryx with a rating of Strong Buy and set a new price target of $110.00 from $107.00 previously
JP Morgan upgraded ChemoCentryx from Underweight to Neutral and set a new price target of $38.00 from $14.00 previously
SVB Leerink upgraded ChemoCentryx from Mkt Perform to Outperform and set a new price target of $64.00
Raymond James upgraded ChemoCentryx from Outperform to Strong Buy and set a new price target of $107.00 from $62.00 previously
Raymond James upgraded ChemoCentryx from Outperform to Strong Buy and set a new price target of $107.00 from $62.00 previously
Piper Sandler upgraded ChemoCentryx from Neutral to Overweight
Stifel upgraded ChemoCentryx from Hold to Buy and set a new price target of $31.00 from $26.00 previously
Raymond James downgraded ChemoCentryx from Strong Buy to Outperform
Raymond James downgraded ChemoCentryx from Strong Buy to Outperform and set a new price target of $51.00 from $120.00 previously
According to data from Benzinga Pro, during Q2, ChemoCentryx's (NASDAQ:CCXI) reported sales totaled $11.76 million. Despite a 18.02% increase in earnings, the company posted a loss of $31.65 million. ChemoCentryx collected $5.46 million in revenue during Q1, but reported earnings showed a $38.61 million loss. Why Is ROCE Significant? Earnings data without context is not clear and can be difficult to base trading decisions on. Return on Capital Employed (ROCE) helps to filter signal from noise by measuring yearly pre-tax profit relative to capital employed by a business. Generally, a higher ROCE suggests successful growth of a company and is a sign of higher earnings per share in the future.
On CNBC’s "Mad Money Lightning Round," Jim Cramer said The Charles Schwab Corporation (NYSE:SCHW) is "terrific." Cramer said he prefers International Flavors & Fragrances Inc. (NYSE:IFF) over Amyris Inc (NASDAQ:AMRS) as the former is doing a "better job." When asked about Canopy Growth Corp (NASDAQ:CGC), Cramer said, "If Canopy Growth is good, then that means that you have one more reason to buy Constellation Brands, Inc. (NYSE:STZ)." The "Mad Money" host said he needs to do some more research on ChemoCentryx Inc (NASDAQ:CCXI). Cramer said he likes TechnipFMC PLC (NYSE:FTI) very, very much. He recommended waiting for a "couple day pullback." When asked about Ardagh Metal Packaging S.
Upgrades According to Stifel, the prior rating for V2X Inc (NYSE:VVX) was changed from Hold to Buy. The current stock performance of V2X shows a 52-week-high of $33.69 and a 52-week-low of $29.55. Moreover, at the end of the last trading period, the closing price was at $29.81. Stifel upgraded the previous rating for Linde PLC (NYSE:LIN) from Hold to Buy. For the second quarter, Linde had an EPS of $3.10, compared to year-ago quarter EPS of $2.70. The stock has a 52-week-high of $352.18 and a 52-week-low of $265.12. At the end of the last trading period, Linde closed at $300.67. Barclays upgraded the previous rating for CF Industries Holdings Inc (NYSE:CF) from Equal-Weight to Overwe
Stifel analyst Dae Gon Ha downgrades ChemoCentryx (NASDAQ:CCXI) from Buy to Hold and lowers the price target from $86 to $52.
ChemoCentryx (NASDAQ:CCXI) reported its Q2 earnings results on Tuesday, August 9, 2022 at 04:05 PM. Here's what investors need to know about the announcement. Earnings ChemoCentryx beat estimated earnings by 10.2%, reporting an EPS of $-0.44 versus an estimate of $-0.49. Revenue was up $9.95 million from the same period last year. Past Earnings Performance Last quarter the company missed on EPS by $0.25 which was followed by a 11.13% increase in the share price the next day. Here's a look at ChemoCentryx's past performance: Quarter Q1 2022 Q4 2021 Q3 2021 Q2 2021 EPS Estimate -0.30 -0.50 -0.45 -0.54 EPS Actual -0.55 -
ChemoCentryx, Inc., (NASDAQ:CCXI), today announced the cancellation of its second quarter 2022 financial results conference call scheduled for Tuesday, August 9, 2022, at 5:00 p.m. ET. The call is being cancelled due to the August 4, 2022, announcement that Amgen and ChemoCentryx, Inc. signed a definitive agreement pursuant to which Amgen would acquire ChemoCentryx. ChemoCentryx filed its Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, on August 8, 2022.
Companies Reporting Before The Bell • Cognition Therapeutics (NASDAQ:CGTX) is estimated to report earnings for its second quarter. • Gilat Satellite Networks (NASDAQ:GILT) is estimated to report quarterly loss at $0.01 per share on revenue of $56.24 million. • Drive Shack (NYSE:DS) is likely to report quarterly loss at $0.10 per share on revenue of $82.58 million. • ReWalk Robotics (NASDAQ:RWLK) is projected to report earnings for its second quarter. • Creative Media (NASDAQ:CMCT) is expected to report earnings for its second quarter. • Anavex Life Sciences (NASDAQ:AVXL) is likely to report earnings for its third quarter. • Dare Bioscience (NASDAQ:DARE) is expected to report quarte
ChemoCentryx (NASDAQ:CCXI) is set to give its latest quarterly earnings report on Tuesday, 2022-08-09. Here's what investors need to know before the announcement. Analysts estimate that ChemoCentryx will report an earnings per share (EPS) of $-0.49. ChemoCentryx bulls will hope to hear the company to announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter. New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast). Past Earnings Performance Last quarter the company missed EPS by $0.25, which was followed by a 11.13% increase
Over the past 3 months, 4 analysts have published their opinion on ChemoCentryx (NASDAQ:CCXI) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 0 3 0 0 Last 30D 0 0 3 0 0 1M Ago 1 0 0 0 0 2M Ago 0 0 0 0 0 3M Ago 0 0 0 0 0 According to 4 analyst offering 12-month price targets in the last 3 months, ChemoCentryx has an average price
Upgrades For 8x8 Inc (NYSE:EGHT), Craig-Hallum upgraded the previous rating of Hold to Buy. In the first quarter, 8x8 showed an EPS of $0.09, compared to $0.01 from the year-ago quarter. At the moment, the stock has a 52-week-high of $17.92 and a 52-week-low of $4.28. 8x8 closed at $4.36 at the end of the last trading period. TD Securities upgraded the previous rating for EOG Resources Inc (NYSE:EOG) from Hold to Buy. EOG Resources earned $2.74 in the second quarter, compared to $1.73 in the year-ago quarter. The current stock performance of EOG Resources shows a 52-week-high of $147.99 and a 52-week-low of $88.29. Moreover, at the end of the last trading period, the closing price was at